The MFN2 Q367H variant from a patient with late-onset distal myopathy reveals a novel pathomechanism connected to mtDNA-mediated inflammation.

Mashiat Zaman¹, Govinda Sharma²*, Walaa Almutawa²*, Tyler GB Soule³, Rasha Sabouny², Matt Joel³, Gerald Pfeffer⁴#, Timothy E. Shutt⁴#

¹Department of Biochemistry & Molecular Biology, Cumming School of Medicine, Hotchkiss Brain Institute, University of Calgary
²Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary
³Department of Neuroscience, Cumming School of Medicine, Hotchkiss Brain Institute, University of Calgary
⁴Hotchkiss Brain Institute, Department of Clinical Neurosciences; and Alberta Child Health Research Institute, Department of Medical Genetics, Cumming School of Medicine, University of Calgary
⁵Departments of Medical Genetics and Biochemistry & Molecular Biology, Cumming School of Medicine, Hotchkiss Brain Institute, Snyder Institute for Chronic Diseases, Alberta Children’s Hospital Research Institute; University of Calgary

*Equal contribution

#Corresponding authors

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

Background

MFN2 encodes a multifunctional mitochondrial protein best known for its role in mitochondrial fusion. While pathogenic variants in MFN2 typically cause Charcot-Marie-Tooth disease subtype 2A, an axonal peripheral neuropathy, exome sequencing identified an uncharacterized MFN2 variant, Q367H, in a patient diagnosed with late-onset distal myopathy without peripheral neuropathy. Although impaired mitochondrial fusion can cause mtDNA-mediated inflammation via TLR9 activation of NF-kB, which is linked to myopathy in a mouse model of MFN1 deficiency, this pathway has not yet been functionally linked to MFN2 pathology.

Methods

To investigate if the Q367H MFN2 variant contributes to the patient phenotype, we applied several biochemical and molecular biology techniques to characterize patient fibroblasts and transdifferentiated myoblasts for several functions mediated by MFN2. We also examined TLR9 and cGAS-STING mtDNA-mediated inflammatory pathways.

Findings

Patient fibroblasts showed changes consistent with impairment of several MFN2 functions. When grown in standard glucose media, patient fibroblasts had reduced oxidative phosphorylation and elevated levels of lipid droplets. When grown in galactose media, patient fibroblasts had fragmented mitochondria, reduced mito-ER contact sites, and enlarged mtDNA nucleoids. Notably, under both media conditions, mtDNA was present outside of the mitochondrial network, where it co-localized with early endosomes. We also observed activation of both TLR9/NF-kB and cGAS-STING inflammation in fibroblasts. Moreover, the inflammatory signaling was increased 3-10 fold in transdifferentiated patient myoblasts, which also exhibited reduced mito-ER contacts and altered mtDNA nucleoids.

Interpretation

We report a patient with myopathy, but without the typical peripheral neuropathy associated with MFN2 disease variants. As elevated inflammation can cause myopathy, linking the Q367H MFN2 variant with elevated TLR9 and cGAS/STING signaling, which is amplified in transdifferentiated myoblasts, provides novel insight into the patient’s phenotype. Thus, we establish a potential novel pathomechanism connecting MFN2 dysfunction to mtDNA-mediated inflammation.
Introduction

Mitochondria are highly dynamic cellular structures that fuse, divide, move about the cell, and interact with other organelles. The integral outer-mitochondrial-membrane (OMM) proteins Mitofusin1 (MFN1) and Mitofusin 2 (MFN2) mediate fusion of the outer mitochondrial membrane. MFN2, though named for its role in mitochondrial fusion, is also actively involved in several other dynamic processes: it mediates contacts between mitochondria and the endoplasmic reticulum (ER) (2), referred to here as mito-ER contact sites (MERCs); is involved in mitochondrial interactions with lipid droplets (3), early endosomes (4), and the nucleus (5); and also plays an active role in mitochondrial autophagy (mitophagy) (6,7).

Pathogenic variants in MFN2 are typically associated with the axonal peripheral neuropathy Charcot-Marie-Tooth disease subtype 2A (CMT2A). Characterized by weakness, numbness and pain in the distal regions of the body, CMT2A is often an early-onset progressively-worsening disease (8). In addition to peripheral neuropathy, patients with certain MFN2 variants can present with other pathogenic phenotypes, such as myopathy (9–11), optic atrophy, sensorineural hearing loss, ataxia (12), or multiple symmetric lipomatosis (MSL) (13–15). How and why different variants in MFN2 lead mechanistically to pathology is not fully understood, though it is likely not as simple as reduced mitochondrial fusion (16).

In addition to its critical role in neurons, MFN2 is also important for muscle function. Muscle-specific MFN2 knockout results in muscle atrophy, which is attributed to loss of mitochondrial fusion and subsequent instability of the mitochondrial genome (mtDNA) (17). On top of the depletion of mtDNA copy number that is thought to contribute to respiratory deficiency, mtDNA can accumulate point mutations and deletions in the muscle tissue of these KO mice. A role for MFN2 in maintaining mtDNA is further supported by the fact that certain pathogenic MFN2 variants show a reduction in mtDNA copy number (18,19) or lead to mtDNA deletions (20). However, highlighting our incomplete understanding of the pathology caused by MFN2 deficiency and the role played by mtDNA, not all pathogenic MFN2 variants impair mitochondrial fusion, impact mtDNA, or cause respiratory deficiency (16).

Beyond its role of encoding OXPHOS proteins, mtDNA is now also recognized to play an important role as an inflammatory signalling molecule when released from mitochondria. Examples of inflammatory signalling pathways that detect mtDNA-mediated include TLR9 (4,18), cGAS-STING (21,22) and the inflammasome (23,24). Notably, a recent study showed that inducible muscle-specific loss of MFN1 causes mtDNA release via early endosomes, leading to activation of TLR9/NF-κB inflammation and myopathy (4). Importantly, pharmacological inhibition of this inflammation improved the muscle atrophy
and physical performance in these mice, implicating sterile inflammation in the muscle pathology of these mice. Nevertheless, the role of mtDNA-mediated inflammation in the pathology of pathogenic MFN2 variants has not been described to date.

Here we report a novel MFN2 variant, Q367H, in a patient diagnosed with late onset distal myopathy. Functional characterization of patient fibroblasts and transdifferentiated myoblasts reveals mtDNA-mediated TLR9 signaling that likely explain the patient myopathy, thus expanding our understanding of the mechanisms by which MFN2 dysfunction contributes to pathology.

**Methods**

**Ethics statement**

The patient provided written informed consent for participation in research and consented to the publication of this report. He was provided with a copy of the draft article prior to submission. Genetic sequencing and human tissue studies with this participant were part of research protocols (REB15-2763 and REB17-0850) approved by the Conjoint Health Research Ethics Board at the University of Calgary.

**Exome Sequencing, Variant Confirmation and Sequence Conservation Study**

DNA was extracted from blood collected into EDTA tubes using standard protocols. Library preparation proceeded using the Ion Ampliseq Exome RDY Panel (Thermo Fisher, A38264) according to manufacturer’s protocol. Automated chip loading and templating used the Ion Chef system and 540 chip/chef kit (Thermo Fisher, A30011), and sequencing was performed on an Ion S5 system (Thermo Fisher, A27212), according to manufacturer’s protocols. Base calling, read alignment to hg19, coverage analysis, and variant calling were performed with Torrent Suite (v. 5.10.1; Thermo Fisher). Similar analysis can be performed using an alternative bioinformatic pipeline as described previously (25).

Patient VCFs were annotated for predicted variant consequence, gnomAD allele frequency, CADD score, and OMIM phenotypes, in addition to default parameters with Ensembl’s command line Variant Effect Predictor (VEP). We additionally aligned off-target reads from exome sequencing to identify any mtDNA variants, as previously described (26).

The variant was verified by Sanger sequencing. Briefly, total genomic DNA was collected using the E.Z.N.A Tissue DNA Extraction Kit (VWR, CA101319-018). The region of interest was amplified using PCR with the following primers (F-GAGAAGAGCAGAGGCTCTTG and R-ACACAGGAATCGTGCTGC).
Subsequently the amplified region was sequenced by Sanger sequencing at University of Calgary Centre For Health Genomics And Informatics. Amino acid sequence alignment was performed using the T-COFFEE online tool (27). The sequences were collected from UniProt(28). The following accession codes were used for the sequences: MFN2: O95140-1, MFN1: Q8IWA4, Mouse MFN2: Q80U63, Fish MFN2: A8WIN6, Chicken MFN2: E1BSH7, Frog MFN2: Q28CS2, Fruit fly MFN: Q7YU24, Worm MFN: Q23424.

Quantification of Protein Amounts:

Relative quantities were measured using Western Blot Analysis, as previously described (12). Briefly, cells were lysed with Pierce RIP A buffer (Thermo Scientific™, 89900), and subsequently total protein was quantified by a BCA assay. 50 μg of protein was loaded from control and patient fibroblasts on to an SDS-PAGE gel. After running the gel, the blots were transferred to a PVDF membrane overnight. The blots were probed using the following antibodies: anti-MFN2 (Abnova, H00009927-M03; 1:1000), anti-MFN1 (Cell Signaling Technology, D6E2S; 1:1000), anti-OPA1 (BD Transduction Laboratories, 612607; 1:1000), anti-Actin (Sigma, A5316; 1:1000). Secondary antibodies complimentary to the primary host species were used- goat anti-rabbit IgG, HRP linked Antibody (Cell Signaling Technology, 7074S) or goat anti-mouse IgG-HRP (Santa Cruz Biotechnology, sc-2055). The membranes were visualized with SuperSignal™ West Femto Maximum Sensitivity Substrate (Thermo Scientific™, 34095) using the Bio-Rad ChemiDoc Imaging System. Bands were quantified using Fiji (29).

Cell Culture and Maintenance

Fibroblasts from the patient and healthy individual were generated through skin biopsies as described (25). The cells were cultured using Minimum Essential Media (Gibco, 11095080), supplemented with 10% Fetal Bovine Serum and 1mM Sodium Pyruvate. Glucose-free conditions were established using DMEM No Glucose media (Gibco, 11966025), supplemented with 5mM galactose, 10% FBS and 1mM Sodium Pyruvate. Cells were grown in an incubator, maintained at 37°C and 5% CO₂. For the fatty acid pulse-chase assay, the cells were grown in the glucose media mentioned above, or glucose-free media with 10% FBS, but no galactose.

Mitochondrial Morphology Analysis

Mitochondrial morphology was analyzed by immunostaining as described previously (30), where 30,000 cells were grown in 12mm coverslips for 24 hours and subsequently fixed by 4% PFA for 20
minutes at 37°C. Cells were permeabilized using 0.1% Triton X-100 (MP Biomedical, J00105) and blocked using 5% FBS. The OMM protein TOMM20 was chosen to visualize the mitochondrial network, where cells were incubated with mouse anti-TOMM20 (Santa Cruz Biotechnology, F-10, RRID: AB_628381) overnight, the subsequently probed with goat anti-mouse secondary conjugated with Alexa fluor 488 (Thermo Fisher Scientific, A-11029). Cover slips were then mounted on glass slides using ProLong Diamond Antifade Mountant with DAPI (Invitrogen, P36966).

Oxygen Consumption Rate

The cellular oxygen consumption rate assay for control and patient fibroblasts was performed as previously described (31). Briefly, 40,000 cells were seeded in wells of the XF-24 plates (Agilent). The media on the plates was replaced 24 hours later with Seahorse CF Base Medium, supplemented with 1mM Pyruvate, 2mM Glutamine and 10mM Glucose and brought to pH 7.4. Post-incubation for 45 minutes with CO₂, cells were loaded into the Seahorse XF24 Analyzer. Oxygen consumption rates were measured at three time points, following administration of Oligomycin (0.5 μM), Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) (1 μM) and Antimycin A (0.5 μM). Following the experiment, cells in each well were lysed with Pierce RIPA buffer and total protein for each well was quantified with BCA assays, for normalization purposes.

mtDNA and Mitochondrial Nucleoid Analyses

Mitochondrial nucleoids were visualized using confocal microscopy as previously reported (32). Briefly, 30,000 control and patient fibroblasts were grown on coverslips for 24 hours and fixed with 4% PFA. Cells were permeabilized with 0.2% Triton X-100 and blocked with 5% FBS. Mitochondrial nucleoids were labelled using mouse anti-dsDNA antibody (Developmental Studies Hybridoma Bank, AB_10805293, RRID:AB_10805293) and subsequently visualized using the goat anti-mouse secondary conjugated with Alexa fluor 488. The mitochondrial network was also labelled using anti-rabbit TOMM20 rabbit anti-TOMM20 (Abcam, ab186735), which was visualized with anti-Rabbit secondary conjugated with Alexa fluor 647 (Thermo Fisher Scientific, A-21245). Cover slips were mounted using ProLong Diamond Antifade Mountant with DAPI.

mtDNA copy number analysis was performed using qPCR. Total DNA was collected from control and patient fibroblasts seeded at the same density. Relative mtDNA copy number was analyzed using nuclear-encoded housekeeping gene 18S, by amplification using the following primers:

mito-F- CACCCAAAGACAAGGT TTGT
For qPCR, 50 ng of total DNA was loaded into each well of a 96-well plate and the reaction was performed using the QuantStudio6 Flex Real-Time PCR system (Thermo Fisher Scientific). The delta Ct method was used to determine the relative copy number.

Long range PCR was done to look for mtDNA deletions using the Takara LA Taq Polymerase (Takara Bio, RR002M). Total DNA was collected from control and patient fibroblasts and 16.2 kBP fragment was amplified using the following primers- (F- ACCGCCGCCACCTCCTCAAGTATCTTCAAGG and R- ACCGCCAGTTTCCAATTTTACGGTGGCTCG). Long Range PCR was done using the following conditions- (94 °C for 1 min; 98 °C for 10 s, and 68 °C for 11 min (30 cycles), followed by a final extension cycle at 72 °C for 10 min). The products following the reaction were visualized by gel electrophoresis on a 0.6% gel run for 18 hours at 18V.

Mito-ER Contact Sites

The proximity ligation assay was used to look for MERCs, using the Duolink In Situ Detection kit (Sigma Aldrich, DUI92008). Briefly, 30,000 control and patient cells were grown on coverslips for 24 hours and subsequently fixed using 4%PFA. Cells were permeabilized with 0.1% Triton X-100 and blocked using the blocking reagent provided by the kit. The cells were then incubated overnight using mouse-anti-Calnexin (Sigma-Aldrich, MAB3126) and rabbit anti-TOMM20 (Abcam, ab186735). Following incubation, PLA probes, complementary to the primary antibodies, anti-mouse (Sigma-aldrich, DUO92004) and anti-rabbit (Sigma-aldrich, DUO92002) were added to the coverslips. The addition of DNA ligase and DNA polymerase were subsequently carried out using manufacturer’s instructions and using the reagents provided in the kit. Finally, secondary antibodies anti-mouse secondary conjugated with Alexa fluor 488 (Thermo Fisher Scientific, A-11029) and anti-Rabbit secondary conjugated with Alexa fluor 647 (Thermo Fisher Scientific, A-21245) were added for visualizing the ER and mitochondrial networks respectively. The coverslips were mounted with ProLong Diamond Antifade with DAPI before imaging.

Lipid Droplets and Fatty Acid Pulse-Chase
Total cellular lipid droplets were labelled using HCS LipidTox Green (Thermo Fisher Scientific, H34350), following the same immunostaining protocol to label the mitochondrial network, except for using 0.1% Saponin (Sigma Aldrich, SAE0073-10G) as the permeabilizing solution. The mitochondrial network was also labelled using anti-rabbit TOMM20 rabbit anti-TOMM20 (Abcam, ab186735), which was visualized with anti-Rabbit secondary conjugated with Alexa fluor 647 (Thermo Fisher Scientific, A-21245).

For the fatty acid pulse-chase assay, 50,000 cells were seeded on a 35mm glass bottom dish with 20mm indented imaging region. Cells were grown for 24 hours, after which they were pulsed with the fluorescent fatty acid precursor BODIPY 558/568 C12 (Invitrogen, D3835). After 24 hours incubation with the BODIPY, cells were incubated with either glucose or glucose-free media and chased at time points 0 hours, 6 hours and 24 hours following the addition of the two media conditions. When the variable media conditions were added, MitoTracker Green (Invitrogen, M7514) was also added at 50nM concentration for visualizing the mitochondrial network.

Mitochondria, mtDNA and Early Endosome Imaging

The triple staining of the mitochondrial network, mtDNA and early endosomes was performed using sequential immunostaining. The steps until blocking are the same as described above for the mitochondrial network. Following blocking, primary antibodies were added for the mtDNA (same as above) and mitochondrial network (same as above) and secondary antibodies were added accordingly- anti-mouse secondary conjugated with Alexa fluor 488 (Thermo Fisher Scientific, A-11029) and anti-Rabbit secondary conjugated with Alexa fluor 568 (Thermo Fisher Scientific, A-11004). Following secondary antibody incubation, coverslips were thoroughly washed with PBS and the primary antibody to label early endosomes was added rabbit anti-RAB5 (Cell Signaling Technology, 3547T). Subsequently, the complementary secondary antibody anti-Rabbit secondary conjugated with Alexa fluor 647 (Thermo Fisher Scientific, A-21245) was added. The coverslips were mounted using ProLong Diamond Antifade mounting media.

Fibroblast Transdifferentiation

The coding sequence for human myoD1 (accession NM_002478) was PCR amplified from a human skeletal muscle cDNA library and subcloned into pWPXL (pWPXL was a gift from Didier Trono (Addgene plasmid # 12257) in place of eGFP at the 5'BamHI and 3'EcoRI restriction sites. The DNA sequence was confirmed using Sanger DNA sequencing.
Lentivirus production was performed using 293FT cells grown to 90% confluency on five, 15 cm² cell culture plates, by cotransfecting 112.5 μg pWPXL-myoD1, 73 μg psPAX2 and 39.5 μg pMD2.G [gifts from Didier Trono (Addgene, plasmid # 12260) using PEIpro transfection reagent (Polyplus). The cell culture media was collected 48 hours post-transfection, quantified using Lenti-X™ GoStix™ Plus (Takara Bio USA, 631280), centrifuged at 500xg for 5 min, 0.45 um filtered and stored at -80°C as 5 mL aliquots. Non-immortalized primary fibroblasts below passage 5 were grown at 37°C, 5% CO₂ in complete media: DMEM – high glucose (Corning, 10-013-CV), 10% FBS (Corning, 35-077-CV), 1% P/S (VWR, K952). T75s or 24 well plates were coated in 0.1 mg/mL VitroCol Type I human collagen (Advanced BioMatrix, 5008) for 1 hour before gently washing with PBS. Cells were seeded at 6,300/cm² and transduced at 75% confluency. 5 μg/mL polybrene (Sigma-Aldrich, TR-1003-G) was mixed with MYOD1 lentivirus at GoStix Values of either 11,500 or 12,000 depending on the biological replicate. Cells were transduced by spinfection, specifically a one-hour spin at 800 xg, RT, and then lentiviral supernatant was replaced with complete media. Media was changed every two days and cells were allowed to transdifferentiate for 7 days before fixing or RNA extraction. Conversion to myoblasts was confirmed by visualization of Desmin using Desmin (D93F5) XP Rabbit mAb (CST, cat. #5332S) and secondary AlexaFluor 594 chicken anti-rabbit (Invitrogen, A-21442). RNA for qPCR was extracted using RNeasy Mini Kit (QIAGEN, 74104).

Analysis of TLR9-NF-kB Signalling Pathways:

The expression of genes associated with the TLR9-NF-kB was analyzed by RT-qPCR. The TLR9 inhibitor Chloroquine (MilliporeSigma, C973P63) and the cGAS-STING inhibitor Ru.521 (Aobious, AOB3 7877) were added to the cell culture media (final concentration 1uM) for 24 hours, and subsequently the cells were washed five times with PBS. Briefly, total RNA was extracted from cells using the HP Total RNA Extraction Kit (VWR, CA101414-852), according to the manufacturer's instructions. The collected RNA was reverse transcribed using the iScript Advanced cDNA Synthesis Kit (BioRad, 1725038). Subsequently, qPCR was performed using the QuantStudio 6 Real-Time PCR system (Thermo Scientific).

The primers used for amplification of target genes are:

- Beta Actin- F- AAGACCTGTACGCAACACAC
- Beta Actin- R- AGTACTTGCCTCAGGAGGA
- Asc-F- CATGACTGATCGACAGGATG
- Asc-R- GGACCTCCTCCAAAATGTTTC
- IL6-F- AGACAGGCACTCACCCTTCTCAG
- IL6-R- TTCTGCCAGTGCCTCTTGTGCTG
Imaging and Analyses

All imaging was performed as previously described (21). The Olympus Spinning Disk Confocal System (Olympus SD OSR) was used with the UAPON 100XOTIRF/1.49 oil objective lens. For live cell imaging, a cellVivo incubation module was used to maintain cells at 37°C and 5% CO₂. For analysis of mitochondrial branch length and footprint, the MiNA plugin (33) was used on Fiji. Number and size of PLA puncta, mitochondrial nucleoids and lipid droplets was performed using the particle analysis tool on Fiji, following thresholding. All co-localization studies were performed using the JaCoP plugin (34) on Fiji. All quantitative figures and statistical tests were performed using GraphPad Prism 9.
Results

Patient Report, Whole Exome Sequencing and Protein Expression for MFN2 Q367H Variant

A male patient in their 70s presented with a two-year history of slowly progressive weakness affecting his lower extremities. Initial symptoms included difficulty walking uphill, and he eventually developed difficulty with stairs and limitations with walking on the ground level and rising from a chair. There were no cramps, fasciculations, or contractures. No sensory loss or coordination. Dysarthria, dysphagia, ptosis, or diplopia were not present.

The patient was medically well and did not have any history of cardiac disease. The parent of the proband developed weakness in her lower legs in her 60s, with progressive limitations in her mobility. Apparently, she was diagnosed with CMT disease, but her clinical profile was not available for review. The parent died in her early 80s due to congestive heart failure. The parent's two siblings aged 76-80, and her other two children aged 40-45 were all unaffected. Clinical examination of the patient demonstrated a cognitively normal individual. Cranial nerve examination was normal. Motor examination revealed MRC grade 4+ strength for ankle dorsiflexion and 4+ plantarflexion bilaterally. Proximal and axial muscle testing was normal, except for Achilles tendon reflexes. The sensory examination was normal. Creatine kinase enzyme activity was elevated to a maximum of 455 U/L (reference range ≤ 195 U/L). The muscle biopsy showed necrotic and regeneration myofiber, myofiber hypertrophy, multifocal endomysia, and perimysial fibrosis, and extensive infiltration by adipose tissue. Immunostaining for dystrophin, alpha/gamma sarcoglycan, skeytin, α-laminin, desmin, and α-β-crystallin was unremarkable. There was no inflammatory cell infiltrate. For the magnetic resonance imaging (MRI) examination, upper and lower legs revealed atrophy in the adductor longus gluteus minimus, tibialis anterior, and inferior gastro-soleus bilaterally [Figure 1A/B].

The case was interpreted as a chronic myopathy nonspecific muscle pathology. A genetic cause was suspected given the family history of a similar condition in his parent, and lack of inflammation on muscle biopsy. Clinical testing with a gene panel encompassing 200 genes associated with myopathy, neuropathy, and neuromuscular disorders identified a previously uncharacterized heterozygous variant in the MFN2 gene, c.1101G>C, p. (Gln367His) [Table 1/Figure 1C]. Research based exome sequencing again identified the MFN2 variant, as well as heterozygous variants of unknown significance in SYNE1 and DYSF (Table 1). While pathogenic variants in SYNE1 can be associated with autosomal dominant neuromuscular disease, this patient variant was not considered to be clinically relevant for the following reasons: (a) the variant is not in the same domain as pathogenic variants previously associated with autosomal dominant disease, (b) SYNE1 variants in this region of the gene have only been associated
with autosomal recessive disorders, while our patient is heterozygous, (c) no characteristic nuclear
abnormalities associated with pathogenic variants in SYNE1 [35] were observed in patient fibroblasts
under microscopy, (d) the myopathy phenotype is not in keeping with the SYNE1-related disease
phenotype, which includes proximal weakness and contractures. Meanwhile, the DYSF variant was not
considered to be an explanation for this patient’s disease because it is a single heterozygous variant in a
condition caused by biallelic variants in DYSF, and we are not aware of any reports of dysferlinopathy
associated with only a single pathogenic variant. Thus, based on strong suspicion for the relationship
between the MFN2 variant and the patient phenotype, we proceeded with the studies described in this
report using patient fibroblast cells.

Characterization of Patient Fibroblasts:

To investigate if the Q367H variant contributes to the patient phenotype, we began by examining
skin fibroblasts obtained from the patient. Immunoblotting for mitochondrial fusion proteins revealed no
significant changes in the expression of MFN2, MFN1, or the inner mitochondrial membrane fusion
protein OPA1 (Figure 1E-J). Next, to determine if this MFN2 variant may contribute to the pathology and
to gain potential insight into the disease mechanism(s), we characterized patient fibroblasts for
alterations to a variety of MFN2-mediated functions.

Mitochondrial Network Morphology and Respiration in MFN2 Q367H Fibroblasts

First, as fibroblast cells from CMT2A patients with MFN2 variants sometimes have fragmented
mitochondria [16], we examined mitochondrial morphology as a potential downstream readout of
altered mitochondrial fusion (Figure 2A-C). No changes were observed under standard culture
conditions. However, glucose-free growth conditions supplemented with galactose, which forces cells to
use mitochondria for energy rather than glycolysis, can be used to detect morphology changes in
fibroblasts from patients with MFN2 variants [36]. Consistent with decreased mitochondrial fusion and
mitochondrial dysfunction, Q367H patient fibroblasts grown in glucose-free galactose-supplemented
media showed a marked increase in the number of cells with fragmented mitochondrial networks, as
well as a decrease in average mitochondrial length. Impairment of mitochondrial function in patient
fibroblasts was further reinforced by functional studies of oxygen consumption. Patient fibroblasts had
increased basal oxygen consumption but reduced maximal oxygen consumption (Figure 2D). As
mitochondrial fragmentation alone does not indicate MFN2 dysfunction (e.g., reduced mitochondrial

326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
health in general can lead to mitochondrial fragmentation), we also explored other functions performed
by MFN2 to provide additional evidence for MFN2 dysfunction.

Perturbated Mitochondrial Nucleoids in MFN2 Q367H Patient Fibroblasts

Mitochondria house their own genome, mtDNA, which is present in hundreds of copies
throughout the mitochondrial network and is organized into nucleoid structures. As mtDNA nucleoids
can be altered by impairments to mitochondrial fusion (37), we sought to examine mtDNA in Q367H
patient fibroblasts (Figure 3A/B). Similar to mitochondrial morphology, there were no changes to mtDNA
nucleoid size or abundance in standard media. However, under glucose-free galactose-supplemented
conditions, patient fibroblasts had a decrease in the average number of mitochondrial nucleoids per cell,
while the average nucleoid size was increased (Figure 3A/C). Of note, in both growth conditions, a small
number of mtDNA nucleoids were observed outside the mitochondrial network in patient fibroblasts
(circled in figure 3A). Meanwhile, the mtDNA copy number did not change under any conditions (Figure
3D/E), nor were any mtDNA deletions detected (Figure 3F). Observing fewer, larger nucleoids without
changes in mtDNA copy number is likely due to nucleoid clustering, a phenotype often observed with
impaired mitochondrial fusion (37). As such, the mtDNA studies are consistent with reduced fusion
leading to mitochondrial fragmentation in the Q367H cells when grown in glucose-free galactose-
supplemented media.

MFN2 Q367H Fibroblasts show reduced number of Mito-ER Contact Sites

MFN2 also mediates mito-ER contact sites (MERCs) (38). As an estimate of MERCs, we used a
proximity ligation assay to detect regions where the mitochondria and ER are within ~40 nm. No
absolute changes in the number or size of the PLA signals were observed in standard media. However,
under glucose-free conditions, Q367H cells had fewer PLA puncta, though these puncta were slightly
larger (Figure 4A-C). As changes in MERCs could be due to global changes in mitochondrial abundance,
we also measured the area of mitochondria (mitochondrial footprint). Importantly, we do not observe
significant differences between mitochondrial footprint in control and patient cells (Figure 4D). However,
when the MERC PLA signal is normalized to the mitochondrial footprint, we see a slight a reduction in
the number of MERCs in the patient fibroblasts in standard conditions, which is further exaggerated
under glucose-free conditions (Figure 4E). Together, these data indicate perturbations in MERCs in the
Q367H fibroblasts that are consistent with MFN2 dysfunction.
Dysfunction in Mitochondrial Fatty Acid Import Leads to Lipid Droplet Accumulation in Patient Fibroblasts

Given the role of MFN2 in mediating mitochondria-lipid droplet interactions, and the fact that lipid droplets are altered in fibroblasts from patients with MFN2 variants (16), we next explored lipid droplets in the Q367H fibroblasts. Interestingly, we see a significant increase in the number and size of cellular lipid droplets in patient fibroblasts, both grown in standard and glucose-free galactose-supplemented media (Figure 5A-D). To explore the mechanism underlying the increased accumulation of lipid droplets, we examined lipid transfer from lipid droplets to mitochondria using an assay that takes advantage of the BODIPY 558/568 fatty acid precursor (39). In this assay, the fluorescently labelled lipid is loaded into lipid droplets during a 24-hour incubation, and its transfer to mitochondria can be monitored over time by microscopy. In control cells in standard conditions, some fatty acid pre-cursor transfers into the mitochondrial network (Figure 5E-F), with higher transfer under glucose starvation conditions (without galactose supplementation). Notably, in patient fibroblasts, no fatty acid trafficking from lipid droplets to mitochondria is observed under either growth condition (Figure 5E-F). These findings suggest that the excess lipid droplets seen in the patient fibroblasts are due to an accumulation of lipids due to a lack of fatty acids transfer from lipid droplets to mitochondria.

MFN2 Q367H Patient Cells Show mtDNA-Mediated Inflammation

Following up on observation of nucleoids outside of the mitochondrial network (Fig 3), we looked for evidence of mtDNA-mediated inflammation, which is linked to impaired mitochondrial fusion and can cause myopathy (4). First, to look for signs for an inflammatory response, we examined the expression of several inflammation genes via q-RT-PCR. Notably, even when cells were grown in standard glucose conditions, we observed an elevation of genes that mediate TLR9 signalling (i.e., ASC/NLRP3/S100A9) and downstream cytokines of the TLR9 pathway (i.e., IL6/TNFα), as well as genes downstream of the cGAS-STING pathway (INF-α/β) (Figure 6A). Similar inflammatory signalling was observed when fibroblasts were grown in galactose media (Supplemental Figure 1). To determine if the increased expression of these genes was due to the TLR9 or cGAS-STING signalling pathways, fibroblasts in standard media were treated with chloroquine to inhibit TLR9 signalling (40), or RU.521 (41) to inhibit cGAS (Figure 6A). Strikingly, chloroquine reduced TLR9 targets, while RU.521 reduced cGAS-STING targets. The fact that each treatment significantly reduced expression of the relevant genes to the levels seen in the control patient fibroblasts, confirms that both TLR9-NF-kB and cGAS-STING signalling are elevated in the patient fibroblasts and that these are the primary pathways driving expression.
Given the link to TLR9 signalling, which detects mtDNA in endosomes, we also looked to see if mtDNA outside the mitochondrial network colocalized with Rab5C-labelled early endosomes. Remarkably, we observed co-localization of extra-mitochondrial mtDNA with early endosomes, including enlarged endosomes harbouring several mtDNA nucleoids (Figure 6B-C). Overall, these findings point to a mtDNA-mediated sterile inflammatory response, mediated through localization of mtDNA into early endosomes and the cytosol (Figure 6D).

**MFN2 Q367H Patient Transdifferentiated Myoblasts Show Elevated Inflammation, Disrupted MERCs and Reduced mtDNA Nucleoid Content**

To examine the cellular and inflammatory phenotypes more closely in a relevant cell type, we transdifferentiated control and patient fibroblasts into myoblasts for additional characterization. Upon transdifferentiating, we still observed increased inflammatory signalling (Figure 7A). However, compared to fibroblast cells, patient myoblasts exhibited an additional 3-fold increase in cGAS-STING interferons, and a 10-fold increase in the TLR9 inflammatory signalling, indicating that these pathways are even more strongly activated in patient muscle cells. Finally, we examined some basic parameters of MFN2 functions in our transdifferentiated patient myoblasts. First, we found no changes in gross mitochondrial morphology or the average length of mitochondrial branches in patient myoblasts (Figure 7B-C). Second, patient myoblasts had fewer MERCs, which were also smaller in size (Figure 7D-F). Finally, the mtDNA nucleoid analysis found a reduction in the number nucleoids per cell in patient myoblasts, as well as a decrease in size of the nucleoids (Figure 7G-I). Notably, consistent with findings in patient fibroblasts, a subset of these nucleoids could be found outside of the mitochondrial network.
Discussion:

We report an individual with a late-onset myopathy phenotype and a previously uncharacterized variant in MFN2. We pursued the investigations described in this report based on strong clinical suspicion for this as a potential pathogenic variant. This sequence change in MFN2 replaces glutamine with histidine at codon 367 of the MFN2 protein (Q367H). The glutamine residue is highly conserved, and there is a small physicochemical difference between glutamine and histidine, implying a hypermorphic change. The MFN2 Q367 amino acid is conserved across vertebrate MFN2 sequences, as well as with the MFN1 parologue (Figure 1D). The MFN2 Q367H variant is present in population databases with a very low allele frequency (highest allele frequency 0.000242 in Gnomad according to dbSNP report rs373211062, accessed June 4, 2024), including one homozygous individual. The variant has an entry in Clinvar (439898, accessed June 4, 2024) and is classified as having conflicting interpretations of pathogenicity, with 4 entries from clinical testing of patients with neurological phenotypes. In a large cohort study, a patient with early onset peripheral neuropathy was reported who was compound heterozygous for Q367H and P184R MFN2 variants (42). However, the Q367H MFN2 variant has not been functionally characterized, or previously reported in the literature as a standalone disease-causing variant. The family history of the patient’s parent suggests autosomal dominant inheritance, which is in keeping with this variant, although confirmation of this variant in the parent was not possible. Furthermore, a different amino acid substitution at this position (Q367P) was associated with a neuropathy presentation (43), providing additional support that variants at this position are likely to be associated with this disease. All considered, the Q367H variant is highly plausible as a reduced penetrance pathogenic variant given its extremely low frequency in population databases, its prevalence in individuals with neurological phenotypes, its presence in published cases from literature. The data from studies in this report point to the deleterious nature of the Q367H variant, and importantly demonstrate the damaging effect of this variant in cells transdifferentiated to the muscle lineage.

This case illustrates many of the challenges when conducting research with people affected by genetic conditions with very late onset. Information from control population databases may be misleading if individuals are presymptomatic for a very late onset disease, or when phenotypes are very mild and slowly progressive. Even for paediatric-onset disease, pathogenic variants appear in a substantial proportion of control individuals (2.8% in one study) (44), and this number may be comparable or even higher for very-late onset disorders, such as the one described in this report. Future research will improve our understanding of genetic variants and disorders with very late onset and...
variable penetrance, but identification and investigation of cases is difficult since they may be mistaken for degenerative or acquired conditions (for example, prior work showing diagnoses of genetic spastic paraplegia in patients initially diagnosed with sporadic primary lateral sclerosis) (45). Other factors include the lack of availability of family members for segregation of variants (i.e., parents have expired by the time the patient is diagnosed, or family members are estranged, or the disease status is not yet known for younger family members). In this respect, we acknowledge limitations of this study which only includes a single affected participant. However, we hope to bring attention to the fact that the investigation of genetic disorders is important to our broader understanding of genetic diseases and operates with the above-mentioned special challenges.

Despite the fact that over 150 MFN2 variants have been reported in patients with CMT2A, we still do not have a complete understanding of how MFN2 dysfunction contributes to disease. The situation is complex, as MFN2 has multiple functions in the cell, and CMT2A can have additional pathological phenotypes beyond peripheral neuropathy. Moreover, only a handful of MFN2 variants have been characterized functionally, and even then, often only for one or two of MFN2's known functions (16). Thus, a better understanding of how MFN2 variants affect MFN2 functions is essential to understanding how MFN2 contributes to disease. Here, our characterization of cells from a patient exhibiting distal myopathy who carried the candidate pathogenic MFN2 Q367H variant provides novel mechanistic insight into MFN2-mediated pathology. The fact that several MFN2-mediated functions are impaired in the patient cells, especially when they are forced to use mitochondria for energy production, supports the notion that the Q367H variant impairs MFN2 function and likely contributes to the patient pathology. Moreover, to our knowledge, the association of mtDNA release and inflammation with an MFN2 variant has not been reported previously, and supports a mechanistic pathway by which MFN2 dysfunction contributes to inflammation. Finally, the elevated levels of inflammation in patient-derived transdifferentiated myoblasts further support a novel disease pathomechanism for MFN2-mediated inflammation driving myopathy.

Several lines of evidence support the pathogenicity of the Q367H MFN2 variant, as patient fibroblasts show perturbation to multiple functions performed by MFN2, including mitochondrial fusion mtDNA nucleoid distribution, MERCs and cellular lipid droplets. With respect to mitochondrial fusion, similar to our findings, several MFN2 variants do not show mitochondrial fragmentation when grown in standard glucose conditions (16). However, culturing fibroblasts in galactose can reveal fragmentation of the mitochondrial network, as reported for MFN2 D210V (9), and as we see for the Q367H variant. This network fragmentation could be caused by reduced fusion and/or increased fission (46). Given the well-
defined role of MFN2 in mitochondrial fusion, the fragmentation is consistent with reduced fusion. Meanwhile, as reduced mitochondrial fusion can also impact mtDNA distribution (37), the changes we see in mitochondrial nucleoids are also consistent with reduced fusion in patient fibroblasts when grown in galactose. Taken together, the results are consistent with reduced mitochondrial fusion when cells are grown in galactose.

Beyond mitochondrial fusion, perhaps the best characterized function of MFN2 is in regulating MERCs (2). Notably, MERCs in fibroblasts from patients with various MFN2 variants can show a variety of changes (16), and the reduction in the number and size of MERCs that we observed in patient cells is consistent with MFN2 dysfunction. Intriguingly, altered MERCs could contribute to the patient myopathy, as pathogenic variants in SEPN1, another gene implicated in MERC biology, also causes a myopathy phenotype (47).

Also consistent with MFN2 dysfunction and in line with our findings, an increased number and size of lipid droplets in fibroblasts is reported in fibroblasts patients with other MFN2 variants (48), as well as upon MFN2 depletion (3). Intriguingly, the lipid droplet phenotype is evident in standard growth conditions when mitochondrial morphology was unaltered. Notably, the mechanism by which impaired MFN2 function leads to increased size and abundance of lipid droplets in patient fibroblasts has not been investigated previously. We envision several possible explanations: decreased transfer of lipids into mitochondria from lipid droplets, or increased transfer of lipids from mitochondria to lipid droplets. Our finding that patient fibroblasts failed to import fatty acids into mitochondria, even under glucose starvation conditions, is in line with the first possibility, and likely reflects the role of MFN2 in mediating mitochondria-lipid droplet interactions (49). Though we expect reduced lipid transfer will also explain the increased lipid droplet accumulation observed in fibroblasts from patients with other MFN2 variants, this remains to be determined.

Characterization of the transdifferentiated patient myoblasts provides further evidence of MFN2 dysfunction and important insight into the muscle myopathy phenotype in the patient. Consistent with MFN2 dysfunction, we see a significant decrease in the number and size of mitochondrial nucleoids, as well as fewer and smaller MERCs in transdifferentiated patient myoblasts. However, we did not observe any changes in mitochondrial network morphology. Notably, the transdifferentiated myoblasts were grown in standard myoblast media, as opposed to the glucose-free galactose-supplemented media required to elicit differences in the patient fibroblasts. Other differences in growth conditions between transdifferentiated patient myoblasts (e.g., collagen matrix), or the inherent differences between fibroblast and myoblast cell types may also explain differences between patient fibroblasts and
transdifferentiated myoblasts. Regardless, the reduced number of nucleoids in the patient cells is consistent with MFN2 dysfunction, as muscle-specific loss of MFN2 leads to mtDNA depletion (17).

The finding of mtDNA release and inflammation in both Q367H patient fibroblasts and transdifferentiated myoblasts is novel in the context of pathogenic MFN2 variants and is likely relevant to disease mechanism. The fact that inhibitors of both TLR9/cGAS-STING pathways lead to decrease in their downstream cytokines, indicates that both pathways are activated. These findings are also consistent with previous work on impaired mitochondrial fusion and increased inflammation. With respect to MFNs, a recent paper by Irazoki et al., found that knockdown of either MFN1 or MFN2 in myoblasts could promote TLR9 signalling (4). Arguing that activation of TLR9-mediated inflammation is a general response to loss of mitochondrial fusion, loss of the inner mitochondrial membrane fusion protein OPA1 in muscle leads to TLR9-mediated NF-κB activation (but not cGAS-STING), where it also drives an inflammatory myopathy (50). Thus, it seems that loss of fusion is sufficient to induce mtDNA-mediated TLR9 inflammation in muscle cells that can drive myopathy. A mechanism that can explain the phenotype of the patient harbouring the Q367H variant. Meanwhile, the increased cGAS-STING signalling that we also see in Q367H patient cells is consistent with increased cGAS-STING activity also reported in MFN2-deficient myoblasts (4), as well as in microglia where MFN2 is downregulated (51). Whether cGAS-STING signalling further perturbs pathology remains to be determined, though elevated cGAS-STING inflammation is also linked to myopathy (52).

Another interesting question involves how MFN2 loss of function drives mtDNA release to stimulate both TLR9 and cGAS-STING inflammation. In this regard, several recent studies are relevant to endosomal-mediated mtDNA release (53–55). A model seems to be emerging where, in the context of stalled mtDNA replication intermediates, enlarged nucleoid clusters are transferred directly into early endosomes, where the mtDNA can be detected by TLR9. When this quality control pathway is overwhelmed, it can lead to release of mtDNA from endosomes into the cytosol, and cGAS-STING activation (54). Notably, one mechanism by which loss of mitochondrial fusion is proposed to impact the mtDNA is through imbalanced distribution of mtDNA maintenance proteins (56), which may lead to an increased abundance of stalled mtDNA replication intermediates. Thus, mtDNA replication fork stalling in response to impaired mitochondrial fusion may trigger initial mtDNA release into endosomes, and the subsequent TLR9 activation associated with MFN2 dysfunction. The fact that we see extra mtDNA and inflammatory signalling in patient cells with normal mitochondrial morphology (e.g., fibroblasts grown in standard media, and differentiated myoblasts), suggests that even subtle alterations in mitochondrial fusion are sufficient to impact the mtDNA. Alternatively (or in conjunction), the differences in MERCs,
which can demarcate sites of mtDNA replication (57,58), could also impair mtDNA replication and trigger to mtDNA release into endosomes.

Meanwhile, as elevated cGAS-STING is not found with MFN1 or OPA1 depletion (4,50,59), the elevated cGAS-STING signalling in myoblasts devoid of MFN2 (4), and seen here in MFN2 Q367H patient cells, suggests another role for MFN2 in mediating mtDNA release beyond just reduced mitochondrial fusion. In this regard, MFN2 can interact with RAB5C on early endosomes (4). As such, it is tempting to speculate that MFN2 has a role in mediating the mitochondrial-endosome interactions required for endosome-mediated removal of stalled mtDNA replication intermediates, and that disrupting this interaction promotes mtDNA escape into the cytosol to activate cGAS-STING inflammation. Future studies examining the mechanisms of mtDNA release will likely provide more insight to the role played by MFN2 and may benefit from examining the Q367H variant as a means to perturb MFN2 function.

It is worth noting that MFN2 could also influence inflammation through its other functions. For example, there are connections between disrupted MERCs and activation of sterile inflammation, particularly in high energy-demanding tissues such as the heart (60). Meanwhile, relevant to the increased lipid droplet abundance associated with MFN2 dysfunction and seen even in standard growth conditions with normal mitochondrial morphology, it is notable that lipid droplet biology intersects with inflammation. Specifically, elevated lipid droplet abundance correlates with increased inflammation (61–64). Overall, our findings are consistent with MFN2 dysfunction contributing to inflammation, which is a possible explanation for myopathy initially described in the proband.

The patient presentation, with late onset myopathy, but without neuropathy, offers a unique opportunity to separate the pathological outcomes of MFN2 dysfunction by examining the specific mechanism leading to myopathy. Although myopathy has been reported previously in patients with CMT2A (10,11), it has always been in the context of a peripheral neuropathy where it is generally considered to be a downstream consequence of nerve loss. For example, the MFN2 D210V variant has myopathy phenotypes in a three-generational case study, which has accompanying axonal neuropathy (9). On the other hand, arguing against the notion of muscle loss downstream of neuropathy, mitochondrial myopathy is seen in a skeletal muscle-specific MFN2 loss-of-function study in animal models, highlighting the importance of the protein in tissues such as skeletal muscle (65,66). Meanwhile, in cardiac muscle, the MFN2 R400Q variant is implicated in cardiomyopathy, though no link to inflammation was investigated (67). Additionally, the loss of MFN2 protein expression in skeletal muscles correlates with age and could contribute to sarcopenia through a similar inflammatory mechanism (68). Finally, similar to the patient we describe here, a novel ENU-induced Mfn2 mouse model characterized

\[
\textit{which can demarcate sites of mtDNA replication (57,58), could also impair mtDNA replication and trigger to mtDNA release into endosomes.}
\]

\[
\text{Meanwhile, as elevated cGAS-STING is not found with MFN1 or OPA1 depletion (4,50,59), the elevated cGAS-STING signalling in myoblasts devoid of MFN2 (4), and seen here in MFN2 Q367H patient cells, suggests another role for MFN2 in mediating mtDNA release beyond just reduced mitochondrial fusion. In this regard, MFN2 can interact with RAB5C on early endosomes (4). As such, it is tempting to speculate that MFN2 has a role in mediating the mitochondrial-endosome interactions required for endosome-mediated removal of stalled mtDNA replication intermediates, and that disrupting this interaction promotes mtDNA escape into the cytosol to activate cGAS-STING inflammation. Future studies examining the mechanisms of mtDNA release will likely provide more insight to the role played by MFN2 and may benefit from examining the Q367H variant as a means to perturb MFN2 function.}
\]

\[
\text{It is worth noting that MFN2 could also influence inflammation through its other functions. For example, there are connections between disrupted MERCs and activation of sterile inflammation, particularly in high energy-demanding tissues such as the heart (60). Meanwhile, relevant to the increased lipid droplet abundance associated with MFN2 dysfunction and seen even in standard growth conditions with normal mitochondrial morphology, it is notable that lipid droplet biology intersects with inflammation. Specifically, elevated lipid droplet abundance correlates with increased inflammation (61–64). Overall, our findings are consistent with MFN2 dysfunction contributing to inflammation, which is a possible explanation for myopathy initially described in the proband.}
\]

\[
\text{The patient presentation, with late onset myopathy, but without neuropathy, offers a unique opportunity to separate the pathological outcomes of MFN2 dysfunction by examining the specific mechanism leading to myopathy. Although myopathy has been reported previously in patients with CMT2A (10,11), it has always been in the context of a peripheral neuropathy where it is generally considered to be a downstream consequence of nerve loss. For example, the MFN2 D210V variant has myopathy phenotypes in a three-generational case study, which has accompanying axonal neuropathy (9). On the other hand, arguing against the notion of muscle loss downstream of neuropathy, mitochondrial myopathy is seen in a skeletal muscle-specific MFN2 loss-of-function study in animal models, highlighting the importance of the protein in tissues such as skeletal muscle (65,66). Meanwhile, in cardiac muscle, the MFN2 R400Q variant is implicated in cardiomyopathy, though no link to inflammation was investigated (67). Additionally, the loss of MFN2 protein expression in skeletal muscles correlates with age and could contribute to sarcopenia through a similar inflammatory mechanism (68). Finally, similar to the patient we describe here, a novel ENU-induced Mfn2 mouse model characterized}
\]
L643P as a variant that causes muscle myopathy without peripheral neuropathy (69). Together, these findings show that MFN2 dysfunction can cause muscle myopathy in the absence of nerve degeneration, as observed in the proband.

With respect to how MFN2 dysfunction might cause myopathy, in the first report of an MFN2-specific mouse muscle knockout, the authors argued that the mtDNA depletion was likely a key contributory factor due to reduced oxidative phosphorylation (65). However, more recent work linking MFN1 and OPA1 muscle deficiency to inflammation mediated myopathy, showed that blocking the inflammation was protective in these models (4,50), arguing for a key role of inflammation in the muscle pathology caused by impaired mitochondrial fusion. Mechanistically, inflammation in the muscle cell niche can lead to myopathy and interfere with muscle stem cell populations (70), as well as affect the expression of myogenic genes (71). Meanwhile, NF-kB, a proinflammatory cytokine that is downstream of TLR9 signaling, can cause muscle wasting in mice (72). Building on these findings, it is tempting to speculate that mtDNA-mediated inflammation may also be relevant to idiopathic inflammatory myopathies, a heterogeneous group of autoimmune disorders with varying clinical manifestations, primarily defined by muscle weakness (73,74). In this regard, we speculate that the mtDNA-mediated inflammation discovered in Q367H patient-derived cells is contributing to the patient’s myopathy.

Although MFN1 and OPA1 deficiency can cause inflammatory myopathy in mouse muscle knockout models, the role of mtDNA-mediated inflammation in MFN2 pathology has not been fully explored. While a mouse knock-in model of the MFN2 K357T variant is linked to augmented neuroinflammation in response to LPS treatment, the role of mtDNA was not investigated (75). Our findings linking the MFN2 Q367H variant to mtDNA release and inflammation thus provide a novel disease mechanism for MFN2 dysfunction. Moreover, while our findings are relevant to the myopathy phenotype in muscle, it is also possible that mtDNA-mediated inflammation contributes to the peripheral neuropathy in neurons. Intriguingly, peripheral neuropathy is a common phenotype of several DNA damaging agents (76–80), such as doxorubicin, which can damage mtDNA and lead to mtDNA-mediated cGAS-STING inflammation (81).

In summary, we observed elevated mtDNA-mediated TLR9/NF-kB and cGAS-STING inflammatory signaling in a patient harboring the uncharacterized MFN2 Q367H variant who displayed late-onset myopathy as a standalone phenotype. Moreover, functional analyses of patient fibroblasts provided several lines of evidence consistent with MFN2 dysfunction. Critically, characterization of transdifferentiated myoblasts and the elucidation of a novel link to mtDNA-mediated inflammation may mechanistically explain the myopathy phenotype in the patient.
Acknowledgements

The authors would like to thank the study participants and their family. Lentivirus production was performed by the Hotchkiss Brain Institute Molecular Core Facility at the University of Calgary.

Author contributions

Designed and/or performed and analyzed mitochondrial experiments, MZ, GS, WA, TS, MJ, RS, GP, and TES; Clinical evaluation of patients, GP; Analyzed exome data GP, MJ; Performed skin biopsy from mitochondrial patients, GP; Drafted the manuscript or figures, MZ, GP, TES. All authors discussed the results and commented on the manuscript. GS, and WA are joint second authors. TES and GP are co-corresponding authors.

Funding

This work was supported by funds provided by the Alberta Children’s Hospital Research Institute (TES), the Canadian Institutes of Health Research (TES), and the New Frontiers Research Fund (TES). MZ was supported by a Hotchkiss Brain Institute International Recruitment Scholarship. WA was supported by the Saudi Cultural Bureau. R.S. was supported by a QEII Graduate Scholarship. TGBS was supported by an Alberta Graduate Excellence Scholarship and a University of Calgary Faculty of Graduate Studies Doctoral Scholarship. MJ is the recipient of the Katharine Sarah Melinda Mei-Ling Thomas Rare Diseases Scholarship. Infrastructure in the lab of GP for this work was supported by the HBI Dementia Research Equipment Fund and a Canada Foundation for Innovation JELF Grant (Neuromuscular Genetics, 36624). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
**Figure Legends:**

**Figure 1: Initial characterization of patient phenotypes and MFN2 Q367H variant.**

A. MRI image at the level of the legs demonstrating predominant atrophy in white arrows; Gastrocnemius (A), Soleus (B) and Tibialis Anterior (C) bilaterally. B. MRI image of upper Thighs demonstrating predominant atrophy of adductor longus gluteus minimus (Not shown here). C.(i) Sanger sequencing results showing single nucleotide polymorphism in patient fibroblasts, transition Guanine to Cytosine. (ii) Topology diagram of MFN2 protein with domains and localization indicated. The site of the Q367H variant is shown in the diagram. D. Amino acid sequence alignment using T-COFFEE tool. E. Western Blot analysis comparing expression of mitochondrial fusion protein in control vs patient fibroblasts, normalized to β-actin. (F-J) Comparison of protein expression levels (F) MFN2 (glucose media) (G) MFN2 (glucose-free/galactose supplemented media) (H) MFN1 (I) OPA1 levels in control vs patient fibroblasts. Data is indicative of mean +/- SD. Statistical comparisons were made by unpaired t-test, (ns=not significant (p>0.05)).

**Figure 2: Changes in mitochondrial morphology and respiratory function.**

(A) Representative confocal images (top) with zoomed inset images (bottom) showing mitochondrial network morphology in control vs patient fibroblasts stained with TOMM20. (B) Qualitative scoring of proportion of cells showing fragmented/intermediate/fused mitochondrial network. Bars indicate mean +/- SD. (C) Quantitative analysis of mean mitochondrial branch length in control vs patient fibroblasts using glucose or glucose-free/galactose supplemented media, bars show mean +/- SD, colours indicate biological replicates. (D) Oxygen Consumption Rate (OCR) assay on control and patient fibroblasts using Seahorse XFe24, bars indicate mean +/- SD (n=12 replicates). Statistical comparisons were made by unpaired t-test (ns=not significant (p>0.05); **** =p≤0.0001).

**Figure 3: Characterization of mtDNA nucleoids, mtDNA copy number, and mtDNA deletions.**

(A) Representative confocal images showing mitochondria (TOMM20; grey) and mitochondrial nucleoids (dsDNA antibody; red) in patient and control fibroblasts under glucose and glucose-free/galactose supplemented nutrient conditions. Circles indicate presence of mtDNA nucleoids outside the mitochondrial network. (B) Number of nucleoids per cell, mean is shown with colours indicating biological replicates. (C) Average size of mitochondrial nucleoids, violin plots show median and interquartile ranges. (D-E) qPCR data showing mitochondrial DNA copy number in (D) glucose and (E) glucose-free/galactose supplemented media, bars indicate mean +/- SD. (F) Agarose gel electrophoresis
showing long range PCR products used to detect full-length or deleted mtDNA and DNA ladder showing corresponding sizes. Statistical comparisons were made by unpaired t-test, (ns=not significant (p>0.05); *=p≤ 0.05; ***=p≤ 0.001; ****=p≤ 0.0001).

Figure 4: Mito-ER Contact site alterations.
(A) Representative confocal images of mito-ER contact sites (MERCs) using proximity ligation assay (PLA) showing mitochondria (TOMM20; cyan), PLA probes (green) and ER (Calnexin; magenta) in glucose and glucose-free/galactose supplemented media. (B) Quantitative analysis of number of MERCs per cell, lines indicate mean +/- SD, colours indicate biological replicates. (C) Quantitative analysis of average size of PLA probes, with violin plots indicate median and interquartile range. (D) Quantitative analysis of mitochondrial area in each cell type in (μm²), lines show mean +/- SD, colours indicate biological replicates. (E) Normalized number of MERCs to total mitochondrial area per cell, lines indicate mean +/- SD, colours indicate biological replicates. P-values determined by unpaired t-test (ns=not significant (p>0.05); *=p≤ 0.05; **=p≤ 0.01; ****=p≤ 0.0001).

Figure 5: Changes to cellular lipid droplets.
(A-B) Representative confocal images showing lipid droplets stained with HCS LipidTox Green in (A) glucose and (B) glucose-free/galactose supplemented media. (C) Quantitative analysis of the average number of lipid droplets per cell, bars indicate mean +/- SD, colours indicate biological replicates. (D) Quantitative analysis of the average size of lipid droplets, violin plots show median and interquartile range. (E) Representative live-cell confocal images showing mitochondria (MitoTracker Green) and fatty acids (BODIPY 558/568) at 0 hours and 24 hours in standard or glucose-starved media. (F) Quantitative analysis of co-localization between fatty acid and mitochondrial network, colours indicate cell type (red-control and blue-MFN2 Q367H), bars indicate mean +/- SD. P-values determined by unpaired t-test (ns=not significant (p>0.05); **=p≤ 0.01; ****=p≤ 0.0001).

Figure 6: MFN2 Q367H cells show activation of TLR9 and cGAS-STING inflammatory pathways, and co-localization of mtDNA with early endosomes.
(A) RT-qPCR data showing gene expression for TLR9/NF-KB targets (Asc, IL6, NLRP3, S100a9, TNF) and cGAS-STING targets (Ifn-α, Ifn-β) in control vs patient fibroblasts under glucose conditions. The graph also shows the effects of inhibitors for the TLR pathway (Chloroquine) or cGAS-STING pathway (RU.521).
Lines indicate mean +/- SD. (B) Representative confocal images showing mitochondria (TOMM20; cyan), mitochondrial nucleoids (anti-dsDNA antibody; green), and early endosomes (RAB5C; magenta). Images in inset bottom right panel highlights the location of mitochondrial nucleoids outside the mitochondria with the early endosomes, denoted by the white arrows. (C) Quantitative analysis of signal co-localization between mitochondrial nucleoids and early endosomes in patient and control fibroblasts determined by Pearson’s coefficient, lines indicate mean +/- SD, points indicate replicates. (D) Pathway model representing mitochondrial dysfunction leading to sterile inflammation. The diagram shows how the MFN2 Q367H variant can alter mitochondrial function, leading to transfer of mtDNA from the mitochondria to the early endosomes (middle). This can lead to detection by TLR9 and subsequent activation of the NF-kB mediated inflammation (right). Additionally, mtDNA in the early endosomes could leak into the cytosol, leading to detection through the cGAS-STING pathway (middle-bottom), promoting Type-I Interferon mediated inflammation (right). Collectively, the inflammation contributes to the distal myopathy disease outcome in the patient. P-values determined by unpaired t-test (ns=not significant (p>0.05); *=p≤0.05; **=p≤0.001).

**Figure 7: Altered MFN2 functions in transdifferentiated patient myoblasts.**

(A) RT-qPCR data showing gene expression for TLR9/NF-KB targets (Asc, IL6, NLRP3, S100a9, TNF) and cGAS-STING targets (Ifn-α, Ifn-β) in control vs patient myoblasts, lines indicate mean +/- SD. (B) Representative confocal images showing mitochondrial network morphology (TOMM20; cyan) in control and patient myoblasts. (C) Quantitative analysis of mean mitochondrial branch length in control and patient myoblasts, violin plots show median and interquartile ranges. (D) Representative confocal images of control and patient myoblasts showing PLA probes (representing MERCs; green), mitochondria (TOMM20; cyan) and ER (Calnexin; magenta). (E) Quantitative analysis of the number of MERCs per cell in control and patient myoblasts, violin plots show media and interquartile ranges. (F) Quantitative analysis of average size of MERCs per cell in control and patient myoblasts, violin plots show media and interquartile ranges. (G) Representative confocal images showing mitochondria (TOMM20) and mitochondrial nucleoids (dsDNA antibody). Circles indicate mtDNA staining outside the mitochondrial network. (H) Quantification of average number of nucleoids per cell in control and patient myoblasts, violin plots show median and interquartile ranges. (I) Quantification of average size of mtDNA nucleoids in control and patient myoblasts. Violin plots show median and interquartile ranges. P-values determined by unpaired t-test (ns=not significant (p>0.05); **=p≤0.001; ****=p≤0.0001).
References


Figure 1

A. C.

B. B.

C. (i) Part of Exon 11 in MFN2 gene

Homo sapiens chromosome 1, GRCh38.p13
(Source: NCBI)

C. (ii)

CAG: Glutamine (Q)
CAC: Histidine (H)

D. 343

GLUTAMINE-367

E. CON Q367H

F. MFN2 86KDa

G. MFN2 No Glucose

H. MFN1 84KDa

I. OPA1 (100-80)KDa

J. B-Actin 42KDa

I. OPA1 β-Actin (% of Controls) ns
**Figure 2**

(A) Glucose Media

- Control
- Q367H

Glucose-Free Media

- Control
- Q367H

(B) Percentage of Cells

- Fused
- Intermediate
- Fragmented

(C) Average mitochondrial length (μm)

- Control Fibroblasts
- Glucose Media
- MFN2 Q367H Glucose Media
- Control Fibroblasts
- Glucose-Free Media
- MFN2 Q367H Glucose-Free Media

(D) Mitochondrial Respiration

- Oligomycin
- FCCP
- Antimycin A

- Control
- MFN2 Q367H

OCR (pmol/min/μg protein)

- Time (minutes)
Figure 3

A. Glucose Media
   Control  Q367H  Control  Q367H
   Mitochondria  dsDNA  Mitochondria  dsDNA  Mitochondria  dsDNA  Mitochondria  dsDNA

B. ns  ***

B. Nucleoids per cell

C. Average nucleoid size (μm²)

D. Glucose Media  Glucose-Free Media
   Control  Q367H  Control  Q367H
   Relative mtDNA Copy Number

E. Glucose Media  Glucose-Free Media
   Control  Q367H  Control  Q367H
   Relative mtDNA Copy Number

F. mtDNA
   kBP  48.5  15
   3
Figure 4

A. Glucose Media

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>MFN2 Q367H</th>
<th>Control</th>
<th>MFN2 Q367H</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitochondria</td>
<td><img src="image1" alt="Image" /></td>
<td><img src="image2" alt="Image" /></td>
<td><img src="image3" alt="Image" /></td>
<td><img src="image4" alt="Image" /></td>
</tr>
<tr>
<td>ER</td>
<td><img src="image5" alt="Image" /></td>
<td><img src="image6" alt="Image" /></td>
<td><img src="image7" alt="Image" /></td>
<td><img src="image8" alt="Image" /></td>
</tr>
<tr>
<td>Inset</td>
<td><img src="image9" alt="Image" /></td>
<td><img src="image10" alt="Image" /></td>
<td><img src="image11" alt="Image" /></td>
<td><img src="image12" alt="Image" /></td>
</tr>
<tr>
<td>Merge</td>
<td><img src="image13" alt="Image" /></td>
<td><img src="image14" alt="Image" /></td>
<td><img src="image15" alt="Image" /></td>
<td><img src="image16" alt="Image" /></td>
</tr>
</tbody>
</table>

B. Number of MERCs/Cell

![Bar graph](image17)

C. Average Area MERCs/Cell

![Box plot](image18)

D. Mitochondrial Footprint (μm)

![Bar graph](image19)

E. Number of MERCs/Total Mitochondrial Area

![Box plot](image20)
A. Control Fibroblasts

B. Control Fibroblasts vs MFN2 Q367H

C. Pearson's Co-localization Coefficient

D. Figure 6
Figure 7

A. mRNA Expression (Fold Change)

B. CONTROL MYOBLASTS
   MFN2 Q367H MYOBLASTS

C. Mean Mitochondrial Branch Length (μm)

D. CONTROL MYOBLASTS
   MFN2 Q367H MYOBLASTS

E. Number of MERCs/Cell

F. Average size of MERCs μm²

G. CONTROL MYOBLASTS
   MFN2 Q367H MYOBLASTS

H. Number of Nucleoids/Cell

I. Average nucleoid size (μm²)
<table>
<thead>
<tr>
<th>Gene</th>
<th>Disease/Inheritance pattern</th>
<th>Coding variant</th>
<th>Amino acid change</th>
<th>rsID</th>
<th>Max reported MAF</th>
<th>ClinVar</th>
<th>Zygosity</th>
<th>Polyphen 2 prediction</th>
<th>Mutation-taster prediction</th>
</tr>
</thead>
<tbody>
<tr>
<td>MFN2</td>
<td>CMT neuropathy 2A; AD</td>
<td>c.1101G&gt;C</td>
<td>p.Gln367His</td>
<td>rs373211062</td>
<td>0.00024</td>
<td>VUS, conflicting interpretations</td>
<td>Heterozygous</td>
<td>B</td>
<td>D</td>
</tr>
<tr>
<td>DYSF</td>
<td>LGMD 2B; AR</td>
<td>c.5180G&gt;C</td>
<td>p.Gly1727Ala</td>
<td>rs146153532</td>
<td>1.16E-04</td>
<td>VUS</td>
<td>Heterozygous</td>
<td>P</td>
<td>D</td>
</tr>
<tr>
<td>SYNE1</td>
<td>EDMD 4; AD/AR</td>
<td>c.9934G&gt;A</td>
<td>p.Aspar312Asn</td>
<td>rs147281213</td>
<td>2.33E-04</td>
<td>VUS</td>
<td>Heterozygous</td>
<td>D</td>
<td>D</td>
</tr>
</tbody>
</table>

AD=autosomal dominant; AR=autosomal recessive; B=benign; CMT=Charcot Marie Tooth; D=deleterious; EDMD=Emery Dreyfuss muscular dystrophy; LGMD=limb girdle muscular dystrophy; MAF=minor allele frequency; P=possibly tolerated; VUS=variant of uncertain significance.